Angela Cacace, Ph.D., is a distinguished scientist who currently holds the position of Chief Scientific Officer at Arvinas, Inc., a biopharmaceutical company focused on developing innovative therapies for cancer and other serious diseases. Dr. Cacace earned her Ph.D. in Molecular Biology from the University of Medicine and Dentistry of New Jersey, and her extensive career in the pharmaceutical industry spans over two decades. Prior to joining Arvinas, she held various leadership roles at companies such as Boehringer Ingelheim and Pfizer, where she was instrumental in advancing drug discovery and development programs. In her role as Chief Scientific Officer at Arvinas, Dr. Cacace is responsible for overseeing the company's research and development efforts, guiding the scientific strategy, and ensuring the successful progression of its pipeline. Her leadership has been pivotal in advancing Arvinas' novel PROTAC (PROteolysis TArgeting Chimera) technology, which has the potential to revolutionize the treatment of various diseases by degrading disease-causing proteins. Under her guidance, Arvinas has made significant strides in clinical development, with several promising drug candidates currently in trials. Dr. Cacace's contributions to the field of drug discovery have been widely recognized, and she has authored numerous scientific publications and patents. Her expertise in oncology and molecular biology, combined with her strategic vision, has positioned Arvinas as a leader in the development of targeted protein degradation therapies. As Chief Scientific Officer, Angela Cacace continues to drive innovation and excellence, working tirelessly to bring life-changing treatments to patients in need.